Key result
PCI yields greater benefit over placebo in patients with lower microvascular resistance.
Why the study?
No placebo-controlled data existed describing the relationship between microvascular resistance and the benefit derived from PCI in stable angina.
Does PCI improve symptoms and exercise capacity compared to placebo in stable angina patients with low microvascular resistance?
RCT
Blinded
Randomized
Does PCI improve symptoms and exercise capacity compared to placebo in stable angina patients with low microvascular resistance?
In patients with stable angina, lower microvascular resistance predicts a greater placebo-controlled symptom and exercise benefit from percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The ability to better identify those likely to derive benefit from PCI and those who may be better suited to medical therapy alone is clearly beneficial but requires prospective evaluation, including MVR diagnostic threshold determination for dichotomizing patients.”
MVR assessment may guide PCI selection in stable angina; extends ORBITA by confirming microvascular resistance modifies placebo-controlled benefit.
No abstract yet. The journal hasn't published one we can show.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Taylor et al. (2026) conducted an RCT in Stable Angina. Percutaneous coronary intervention (PCI) vs. Placebo was evaluated on Placebo-controlled changes in treadmill exercise time, patient-reported symptoms, physician-assessed symptoms, and dobutamine stress echocardiography scores. The placebo-controlled benefit of percutaneous coronary intervention was greater in patients with lower microvascular resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: